IMO the company is likely looking for another deal in 2024 as a...

IMO the company is likely looking for another deal in 2024 as a pre cursor to raising money. This would provide the opportunity for Peak and certain others to get reset through a new deal and a deeply discounted capital raise.

IMO the existing idea doesn’t have any genuinely defendable IP, but rather it’s a feeble narrative on the headline economic number associated with pain. Inhaler technology is dominated by bigger groups like Philip Morris as we’ve discussed and there’s no IP position to exploit with generic Dronabinol. So what is the actual idea that would create any value?

And as you stated accurately, it’s not great that they’ve allowed the coffers to get so low. That suggests there’s no appetite for raising capital for this project so perhaps the market agrees with the above synopsis.